Development of a New Experimental Model of Penicillin-Resistant *Streptococcus pneumoniae* Pneumonia and Amoxicillin Treatment by Reproducing Human Pharmacokinetics

LIONEL PIROTH,1 LAURENT MARTIN,2 ALEXIS COULON,1 CATHERINE LEQUEU,1 MICHEL DUONG,1 MARIELLE BUISSON,1 HENRI PORTIER,1 AND PASCAL CHAVANET1*

Service des Maladies Infectieuses et Tropicales, Microbiologie Médicale et Moléculaire (EA562), Hôpital du Bocage,1 and Service d’Anatomie Pathologique, Centre Hospitalier Universitaire de Dijon,2 Dijon Cedex, France

Received 25 September 1998/Returned for modification 20 February 1999/Accepted 16 June 1999

The increase of penicillin-resistant *Streptococcus pneumoniae* (PRSP) pneumonia results in a greater risk of antibiotic treatment failure. In vitro data are not sufficient predictors of clinical efficacy, and animal models may be insufficiently contributive, since they often use immunocompromised animals and do not always respect the human pharmacokinetics of antibiotics. We developed an experimental PRSP pneumonia model in immunocompetent rabbits, by using intrabronchial instillation of PRSP (MIC = 4 mg/liter), without any adjuvant. This reproducible model was used to assess amoxicillin efficacy by reproducing human serum pharmacokinetics following 1-g oral or intravenous administrations of amoxicillin every 8 h. Evaluation was performed by using clinical, CT scan, macroscopic, histopathologic, and microbiological criteria. Experimental pneumonia in untreated rabbits was similar to untreated severe human bacteremic untreated pneumonia; in both rabbits and humans, (i) cumulative survival was close to 50%, (ii) red or gray lung congestion and pleuritis were observed, and (iii) lung and spleen concentrations reached 5 and 4 log_{10} CFU/g. A 48-h treatment resulted in a significant bacterial clearance in the lungs (1.53 versus 5.07 log_{10} CFU/ml, P < 0.001) and spleen (1.00 versus 4.40 log_{10} CFU/ml, P < 10^{-4}) and a significant decrease in mortality (0% versus 50%, P = 0.02) in treated versus untreated rabbits. No difference was observed on macroscopic and histopathologic lesions between treated and untreated rabbits (P = 0.36 and 0.78, respectively). Similar results were obtained by using a fully penicillin-susceptible *S. pneumoniae* strain (MIC = 0.01 mg/liter). Our findings suggest that (i) this new model can be contributive in the evaluation of antibacterial agents and (ii) 1 g of amoxicillin three times a day may be sufficient to treat PRSP pneumonia in immunocompetent humans.

Invasive *Streptococcus pneumoniae* infection is a worldwide problem. *S. pneumoniae* is the most common cause of bacterial pneumonia, leading to significant morbidity and mortality rates which vary around 25% (5, 37, 51). Since the first reports three decades ago of strains of *S. pneumoniae* with a decreased susceptibility to penicillin, there have been increasing reports of pneumococcal infections caused by strains with high levels of resistance to penicillin and to multiple antibiotics (5, 25, 36, 37, 51). Clinical treatment failures in patients with infections caused by penicillin-resistant *S. pneumoniae* point out the interest for more evaluation of therapeutic efficacy. Indeed, in vitro data are only mildly helpful because of their incapacity to predict clinical therapeutic success (5). Furthermore, human therapeutic trials are very difficult to conduct, because of the impossibility of clinically evaluating the situation, due to penicillin-resistant pneumococcal infection, and the great prevalence of precessive antibiotherapy, which reduces the probability of isolating penicillin-resistant *S. pneumoniae*, even after treatment failure. Consequently, animal models could contribute to predicting antibiotic treatment efficacy in such infections.

Several penicillin-resistant *S. pneumoniae* animal models exist (1–3, 6, 9, 14, 17, 18, 33, 34, 39, 41–43, 45, 46). However, the greatest difficulty for these models was the inability to infect healthy animals with penicillin-resistant *S. pneumoniae* strains. Consequently most of the available models were developed in immunocompromised mice (1–3, 6, 9, 14, 17, 33, 34, 42, 43) and young rodents (9, 41, 45, 46) or used adjuvant to enhance bacterial virulence (9, 18, 39, 41). Moreover, differences between animal and human pharmacokinetics constituted another important limit.

In the present study, we developed a model of experimental penicillin-resistant *S. pneumoniae* pneumonia using nonimmunosuppressed animals (adult New Zealand rabbits), reproducing human pathology with an inoculum free of any adjuvant. We also reproduced human serum pharmacokinetics following amoxicillin administration. In a third phase, we conducted an experimental therapeutic study in order to evaluate the amoxicillin (3 g/day) efficacy on bacterial clearance in penicillin-resistant *S. pneumoniae* pneumonia, corresponding to the dose recommended in France for pneumonia treatment (44).

(This work was presented in part at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif., 1998.)

MATERIALS AND METHODS

**Microorganisms.** Two *S. pneumoniae* strains isolated from the blood of patients with pneumonia were used (kindly provided by Geslin of the Centre National de Référence des Pneumocoques, Créteil, France). The first strain (strain 145, serotype 19) was fully susceptible to penicillin (MIC = 0.01 mg/liter). The second strain (strain 16089, serotype 9V) was highly resistant to penicillin (MIC = 4 mg/liter) and less susceptible to amoxicillin (MIC = 2 mg/liter) and ceftriaxone (MIC = 1 mg/liter). Purity was confirmed throughout the study by Gram staining and colony morphology. Working stock cultures were kept frozen at –70°C in a 15% glycerol supplemented brain heart infusion (BioMérieux Laboratories, Marcy l’Etoile, France). In order to maintain virulence, stock
TABLE 1. Macrosopic scoring grid

<table>
<thead>
<tr>
<th>Score</th>
<th>Aspect</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Normal</td>
</tr>
<tr>
<td>1</td>
<td>Scar</td>
</tr>
<tr>
<td>2</td>
<td>Slight congestion</td>
</tr>
<tr>
<td>3</td>
<td>Red congestion</td>
</tr>
<tr>
<td>4</td>
<td>Gray congestion</td>
</tr>
<tr>
<td>5</td>
<td>Yellowish congestion</td>
</tr>
</tbody>
</table>

cultures were changed every month by using the colonies isolated from rabbits with untreated S. pneumoniae pneumonia.

Before each experiment, several S. pneumoniae strains from one aliquot (per strain) were inoculated into brain heart infusion, cultured on agar plates, and incubated for 24 h at 37°C in 5% CO2. Twenty-five to 30 colonies were taken and inoculated into 9 ml of brain heart infusion, incubated for 6 h at 37°C, and then cultured on agar plates for 18 h at 37°C in 5% CO2. This culture was diluted in physiologic saline in order to obtain final concentrations of 7, 8.5, and 10 log_{10} CFU/ml. No adjuvant was used. These concentrations were first determined by using optic density measure, in reference to a standard curve, and confirmed by using successive dilution cultures.

**Animals.** Male New Zealand White rabbits (body weight, 2.7 to 3.0 kg) were obtained from Elevage Scientifique des Dombes (Romans, France). These animals were not immunosuppressed and had a sanitary status of virus antibody free. Mice were obtained from Elevage Scientifique des Dombes (Romans, France). These animals were not immunosuppressed and had a sanitary status of virus antibody free. The animals were anesthetized intramuscularly with 1.5 ml of a mixture of ketamine (500 mg/ml) and xylazine (2.75 mg/ml). A silicone catheter was introduced into the jugular vein, through a lateral incision of the neck, and then subcutaneously tunneled through the interscapular area (50). This catheter was introduced in order to subsequently infuse antibiotics at human pharmacokinetic rates.

Twenty-four hours later, the rabbits were anesthetized intravenously by using 0.8 ml of the ketamine plus-xylazine mixture and then by a few milliliters of propofol as needed. Under view control, a silicone catheter (Sigma Medical, Nanterre, France) was introduced through the vocal cords into the trachea and pulled till it reached the bronchia. Freshly prepared pneumococcal inoculum (0.5 ml) was then gently flushed through this catheter. The endobronchial catheter was then immediately removed after the inoculum instillation, and the animals were placed upright for 15 s to facilitate distal alveolar migration by gravity.

Using the same experimental conditions, some rabbits were inoculated with heat-killed penicillin-resistant S. pneumoniae as negative controls.

**Experimental pneumococcal pneumonia in rabbits.** The animals were anesthetized intramuscularly with 1.5 ml of a mixture of ketamine (500 mg/ml) and xylazine (2.75 mg/ml). A silicone catheter was introduced into the jugular vein, through a lateral incision of the neck, and then subcutaneously tunneled through the interscapular area (50). This catheter was introduced in order to subsequently infuse antibiotics at human pharmacokinetic rates.

Twenty-four hours later, the rabbits were anesthetized intravenously by using 0.8 ml of the ketamine plus-xylazine mixture and then by a few milliliters of propofol as needed. Under view control, a silicone catheter (Sigma Medical, Nanterre, France) was introduced through the vocal cords into the trachea and pulled till it reached the bronchia. Freshly prepared pneumococcal inoculum (0.5 ml) was then gently flushed through this catheter. The endobronchial catheter was then immediately removed after the inoculum instillation, and the animals were placed upright for 15 s to facilitate distal alveolar migration by gravity. Using the same experimental conditions, some rabbits were inoculated with heat-killed penicillin-resistant S. pneumoniae as negative controls.

**Experimental pneumococcal pneumonia in rabbits.** The animals were anesthetized intramuscularly with 1.5 ml of a mixture of ketamine (500 mg/ml) and xylazine (2.75 mg/ml). A silicone catheter was introduced into the jugular vein, through a lateral incision of the neck, and then subcutaneously tunneled through the interscapular area (50). This catheter was introduced in order to subsequently infuse antibiotics at human pharmacokinetic rates.

Twenty-four hours later, the rabbits were anesthetized intravenously by using 0.8 ml of the ketamine plus-xylazine mixture and then by a few milliliters of propofol as needed. Under view control, a silicone catheter (Sigma Medical, Nanterre, France) was introduced through the vocal cords into the trachea and pulled till it reached the bronchia. Freshly prepared pneumococcal inoculum (0.5 ml) was then gently flushed through this catheter. The endobronchial catheter was then immediately removed after the inoculum instillation, and the animals were placed upright for 15 s to facilitate distal alveolar migration by gravity. Using the same experimental conditions, some rabbits were inoculated with heat-killed penicillin-resistant S. pneumoniae as negative controls.

**Experimental pneumococcal pneumonia in rabbits.** The animals were anesthetized intramuscularly with 1.5 ml of a mixture of ketamine (500 mg/ml) and xylazine (2.75 mg/ml). A silicone catheter was introduced into the jugular vein, through a lateral incision of the neck, and then subcutaneously tunneled through the interscapular area (50). This catheter was introduced in order to subsequently infuse antibiotics at human pharmacokinetic rates.

Twenty-four hours later, the rabbits were anesthetized intravenously by using 0.8 ml of the ketamine plus-xylazine mixture and then by a few milliliters of propofol as needed. Under view control, a silicone catheter (Sigma Medical, Nanterre, France) was introduced through the vocal cords into the trachea and pulled till it reached the bronchia. Freshly prepared pneumococcal inoculum (0.5 ml) was then gently flushed through this catheter. The endobronchial catheter was then immediately removed after the inoculum instillation, and the animals were placed upright for 15 s to facilitate distal alveolar migration by gravity. Using the same experimental conditions, some rabbits were inoculated with heat-killed penicillin-resistant S. pneumoniae as negative controls.

**Experimental pneumococcal pneumonia in rabbits.** The animals were anesthetized intramuscularly with 1.5 ml of a mixture of ketamine (500 mg/ml) and xylazine (2.75 mg/ml). A silicone catheter was introduced into the jugular vein, through a lateral incision of the neck, and then subcutaneously tunneled through the interscapular area (50). This catheter was introduced in order to subsequently infuse antibiotics at human pharmacokinetic rates.

Twenty-four hours later, the rabbits were anesthetized intravenously by using 0.8 ml of the ketamine plus-xylazine mixture and then by a few milliliters of propofol as needed. Under view control, a silicone catheter (Sigma Medical, Nanterre, France) was introduced through the vocal cords into the trachea and pulled till it reached the bronchia. Freshly prepared pneumococcal inoculum (0.5 ml) was then gently flushed through this catheter. The endobronchial catheter was then immediately removed after the inoculum instillation, and the animals were placed upright for 15 s to facilitate distal alveolar migration by gravity. Using the same experimental conditions, some rabbits were inoculated with heat-killed penicillin-resistant S. pneumoniae as negative controls.

**Experimental pneumococcal pneumonia in rabbits.** The animals were anesthetized intramuscularly with 1.5 ml of a mixture of ketamine (500 mg/ml) and xylazine (2.75 mg/ml). A silicone catheter was introduced into the jugular vein, through a lateral incision of the neck, and then subcutaneously tunneled through the interscapular area (50). This catheter was introduced in order to subsequently infuse antibiotics at human pharmacokinetic rates.

Twenty-four hours later, the rabbits were anesthetized intravenously by using 0.8 ml of the ketamine plus-xylazine mixture and then by a few milliliters of propofol as needed. Under view control, a silicone catheter (Sigma Medical, Nanterre, France) was introduced through the vocal cords into the trachea and pulled till it reached the bronchia. Freshly prepared pneumococcal inoculum (0.5 ml) was then gently flushed through this catheter. The endobronchial catheter was then immediately removed after the inoculum instillation, and the animals were placed upright for 15 s to facilitate distal alveolar migration by gravity. Using the same experimental conditions, some rabbits were inoculated with heat-killed penicillin-resistant S. pneumoniae as negative controls.

**Experimental pneumococcal pneumonia in rabbits.** The animals were anesthetized intramuscularly with 1.5 ml of a mixture of ketamine (500 mg/ml) and xylazine (2.75 mg/ml). A silicone catheter was introduced into the jugular vein, through a lateral incision of the neck, and then subcutaneously tunneled through the interscapular area (50). This catheter was introduced in order to subsequently infuse antibiotics at human pharmacokinetic rates.

**Experimental pneumococcal pneumonia in rabbits.** The animals were anesthetized intramuscularly with 1.5 ml of a mixture of ketamine (500 mg/ml) and xylazine (2.75 mg/ml). A silicone catheter was introduced into the jugular vein, through a lateral incision of the neck, and then subcutaneously tunneled through the interscapular area (50). This catheter was introduced in order to subsequently infuse antibiotics at human pharmacokinetic rates.

**Experimental pneumococcal pneumonia in rabbits.** The animals were anesthetized intramuscularly with 1.5 ml of a mixture of ketamine (500 mg/ml) and xylazine (2.75 mg/ml). A silicone catheter was introduced into the jugular vein, through a lateral incision of the neck, and then subcutaneously tunneled through the interscapular area (50). This catheter was introduced in order to subsequently infuse antibiotics at human pharmacokinetic rates.

**Experimental pneumococcal pneumonia in rabbits.** The animals were anesthetized intramuscularly with 1.5 ml of a mixture of ketamine (500 mg/ml) and xylazine (2.75 mg/ml). A silicone catheter was introduced into the jugular vein, through a lateral incision of the neck, and then subcutaneously tunneled through the interscapular area (50). This catheter was introduced in order to subsequently infuse antibiotics at human pharmacokinetic rates.

**Human-simulated amoxicillin treatment.** Eighteen rabbits were randomly assigned just before inoculation with 0.5 ml of 10^7 CFU/ml of penicillin-resistant S. pneumoniae (strain 16089) per ml to three arms: (i) untreated (n = 8), (ii) oral

**TABLE 2. Histopathologic scoring**

<table>
<thead>
<tr>
<th>Score</th>
<th>Aspect</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Normal</td>
</tr>
<tr>
<td>1</td>
<td>Vascular lesions</td>
</tr>
<tr>
<td>2</td>
<td>Bronchitis</td>
</tr>
<tr>
<td>3</td>
<td>Focal bronchopneumonia</td>
</tr>
<tr>
<td>4</td>
<td>Confluent bronchopneumonia</td>
</tr>
<tr>
<td>5</td>
<td>Lung abscesss</td>
</tr>
</tbody>
</table>
amoxicillin treated (n = 5), and (iii) intravenous amoxicillin treated (n = 5). The same procedure was used in a second group inoculated with 0.5 ml of 10 log_{10} CFU of penicillin-susceptible S. pneumoniae (strain 195) per ml. Human-like amoxicillin treatment was started 4 h after inoculation. Four doses of 1 g of amoxicillin (every 8 h) were simulated in the oral-treated arms, while five doses of 1 g of amoxicillin (every 8 h) were simulated in the intravenous-treated arm. Blood samples were taken in treated rabbits to assess the quality of the human pharmacokinetics simulation. All treated rabbits still alive were sacrificed 10 h after inoculation, i.e., around 48 h after inoculation. Untreated rabbits still alive were also sacrificed 48 h after inoculation.

Amoxicillin concentrations in the serum and lungs were systematically assayed at death time in treated rabbits. Evaluation criteria were survival, macroscopic, and histopathologic scores and pneumococcal concentrations in lungs and spleen at death time in treated rabbits. Evaluation criteria were survival, macroscopic, and histopathologic scores; macroscopic score; histopathologic score; lung pneumococcal concentrations; spleen pneumococcal concentrations.

RESULTS

Experimental pneumococcal pneumonia in rabbits. Cumulative survival rates of rabbits with experimental pneumonia produced by inoculation of penicillin-resistant S. pneumoniae (strain 16089) at 7, 8.5, and 10 log_{10} CFU/ml, compared with penicillin-susceptible S. pneumoniae (strain 195) at 10 log_{10} CFU/ml, are shown in Fig. 1. With the inoculum of 10 log_{10} CFU/ml, the first pneumonia-related deaths occurred 6 h after inoculation, most of them during the first 72 h, with very few events after this time. With the inocula of 7 and 8.5 log_{10} CFU/ml, no pneumonia-related deaths were observed. So there was a significant difference between the cumulative survival observed after inoculation of 7 or 8.5 log_{10} CFU/ml and that observed with 10 log_{10} CFU of penicillin-resistant S. pneumoniae per ml (7 versus 10 log_{10} CFU/ml, P < 0.05, log-rank test, and 8.5 versus 10 log_{10} CFU/ml, P < 0.05, log-rank test). There was no difference between cumulative survival observed after inoculation with 10 log_{10} CFU of penicillin-resistant S. pneumoniae per ml and 10 log_{10} CFU of penicillin-susceptible S. pneumoniae per ml (P = 0.46, Peto’s Khi2 test).

Inoculation of 7 and 8.5 log_{10} CFU of penicillin-resistant S. pneumoniae per ml induced few to moderate macroscopic and histopathologic lesions and mild bacterial concentrations (data not shown). Evolutions of macroscopic, histopathologic, and bacterial concentrations observed with 10 log_{10} CFU of penicillin-resistant S. pneumoniae per ml inocula are shown in Fig. 2. Four hours after inoculation, a significant bacteremic pneumonia was already observed, with pneumococcal concentrations reaching 5 log_{10} CFU/g in lungs and 3 log_{10} CFU/g in the spleen. Histopathologic and macroscopic scores were close to 10 at this time. Bacteremia (as spleen pneumococcal culture) then reached a peak concentration around 24 h. Lung pneumococcal concentrations followed the same pattern. CT scan examinations showed a lobar condensation first in a lower lobe (Fig. 3), with rapid extension to the other lobes within 72 h (Fig. 4A to C). These CT scan aspects are very close to those observed in humans. The main macroscopic aspects were red congestion at 12 h and gray congestion at 24 h. Lung histopathologic examination at 24 h showed a slight increase of leukocytes and a few erythrocytes within the alveoli and bronchial lumen (Fig. 5A). At 48 h, the alveolar spaces were filled up with a large number of polymorphonuclear leukocytes and fibrinous exudate (Fig. 5B).

As a comparison, pulmonary lesions and bacterial evolution observed after instillation of 10 log_{10} CFU of penicillin-susceptible S. pneumoniae per ml are shown in Fig. 6. A similar evolution was observed, even if lung lesions were considered to be less important than with the penicillin-resistant S. pneumoniae strain. Thus, this inoculum of 10 log_{10} CFU/ml was used for the experiments for both penicillin-resistant S. pneumoniae and penicillin-susceptible S. pneumoniae pneumonia.
Differences observed between sacrificed rabbits and rabbits killed by pneumonia at 24 and 48 h are summarized in Table 3. Lung and spleen pneumococcal concentrations were significantly different at 24 h, according to cause of death, whereas no difference was observed at 48 h. On the other hand, macroscopic and histopathologic lesions were not different at 24 h, but a significant difference existed at 48 h. Thoracic CT scan examination at 12 h did not show any difference between rabbits which survived pneumonia and those which died of it at 24 h.

There was a clear and significant correlation between macroscopic and histopathologic scores ($r = 0.57$, $P < 10^{-6}$), as well as between bacterial contents in lungs and spleen ($r = 0.67$, $P < 10^{-6}$). There was also a weak but significant correlation between pneumococcal pulmonary concentrations and macroscopic or histopathologic scores ($r = 0.21$, $P < 10^{-6}$; and $r = 0.12$, $P < 10^{-4}$, respectively).

As expected, neither deaths nor pulmonary lesions (either macroscopic or histopathologic) were induced by inoculation of heat-killed penicillin-resistant S. pneumoniae (negative controls).

**Simulation of human amoxicillin pharmacokinetics in rabbits.** Amoxicillin concentrations in serum following the infusion of a 20-mg/kg bolus in four rabbits fitted into a bicomartmental model, as shown in Fig. 7. Constants were as follows: A, 155 mg/liter; B, 12 mg/liter; $\alpha$, 15 h$^{-1}$; and $\beta$, 1.5 h$^{-1}$. The observed area under the curve was equal to 15.55 mg·h$^{-1}$·liter$^{-1}$. The correlation coefficient between observed and calculated values was 0.996. The time above MIC in serum was 45 and 150 min for penicillin-resistant S. pneumoniae and penicillin-susceptible S. pneumoniae, respectively.

Simulations of human pharmacokinetics following oral ($n = 14$ rabbits) or intravenous ($n = 8$ rabbits) amoxicillin (1 g) administration are shown in Fig. 8A and B. Cumulative daily doses of amoxicillin used to reproduce both intravenous and oral human profiles in rabbits were close to 170 mg/kg. Mean areas under curves were equal to 60.36 for oral and 63.58 mg·h$^{-1}$·liter$^{-1}$ for intravenous administration, and times above MIC for the penicillin-resistant S. pneumoniae strain were 360 and 190 min, respectively. Correlation coefficients and area under the curve ratios, between observed and expected values, were 0.988 and 1.08 for oral simulation and 0.998 and 1.15 for intravenous simulation, respectively. The mean measured pulmonary amoxicillin concentration 1 h after intravenous simulation initiation was 22.3 mg/liter.

**Human-simulated amoxicillin treatment of experimental penicillin-resistant pneumococcal pneumonia in rabbits.** For the penicillin-resistant S. pneumoniae pneumonia model (strain 16089), observed peak amoxicillin concentrations in serum were 14.21 mg/liter for oral simulation and 92.85 mg/liter for intravenous simulation, with expected values of 19.7 and 101 mg/liter, respectively. Correlation coefficients and area under the curve ratios between observed and expected values were 0.917 and 0.66 (oral simulation) and 0.997 and 0.89 (intravenous simulation), respectively. In all the treated rabbits, measured amoxicillin pulmonary concentrations were always below 1 mg/liter at the time of the sacrifice (around 48 h after inoculation). Pneumococcal concentrations in lungs and spleen were significantly lower in treated arms than in untreated arms (orally treated versus untreated, $P = 0.005$ and $P < 10^{-6}$, and intravenously treated versus untreated, $P = 0.004$ and $P < 10^{-6}$, respectively; Dunnett’s test) (Table 4). There was no difference between the two treated arms. On the other hand, macroscopic and histopathologic evaluations were not different within the three arms. Results observed for the three arms 48 h after inoculation of the penicillin-resistant S. pneumoniae (strain 16089) group are summarized in Table 4.

In the penicillin-susceptible S. pneumoniae pneumonia model (strain 195), observed concentrations in serum at peak were 19.93 mg/liter in oral simulation and 126.36 mg/liter in intravenous simulation, with expected values of 19.7 and 101 mg/liter, respectively. Correlation coefficients and area under the curve ratios between observed and expected values were 0.953 and 0.80 (oral simulation) and 0.992 and 1.46 (intravenous simulation), respectively. As for the penicillin-resistant S. pneumoniae pneumonia model, in all the treated rabbits measured amoxicillin pulmonary concentrations were always below 1 mg/liter at the time of the sacrifice. Pneumococcal concentrations in lungs and spleen were also significantly different between treated and untreated arms (orally or intravenously treated versus untreated; macroscopic or histopathologic score, $P < 10^{-6}$; Dunnett’s test). There was no difference between the two

FIG. 3. CT scan examination of penicillin-resistant S. pneumoniae (strain 16089) experimental pneumonia at 24 h. The alveolar condensation of the entire left lower lobe (+) is due to active pneumonia, in contrast with normal aspects of the right lower and median lobes.
treated arms. On the other hand, macroscopic and histopathologic evaluations were not different within the three arms. Results observed for the three arms 48 h after inoculation in the penicillin-susceptible *S. pneumoniae* (strain 195) group are summarized in Table 4.

**DISCUSSION**

Experimental penicillin-resistant *S. pneumoniae* pneumonia in rabbits. The primary purpose of our study was to develop a penicillin-resistant *S. pneumoniae* pneumonia model in parallel with a penicillin-susceptible *S. pneumoniae* pneumonia model. Several animal models have been published (1–3, 6, 9, 14, 17, 18, 33, 34, 39, 41–43, 45, 46). However, although these models are contributive, our model exhibits several advantages. The strains used in our study were clinical isolates with common serotypes. The use of conventional adult male New Zealand White rabbits offered the following two advantages. (i) They were not naturally susceptible to *S. pneumoniae* infections (4), which guarantees that the observed pathologies were induced by experiments. (ii) They were not immunosuppressed, in contrast to most of the animals used in other penicillin-resistant *S. pneumoniae* pneumonia models (1–3, 6, 9, 14, 17, 33, 34, 42, 43). Inoculation through natural airways into bronchia was more reproducible than aerosols or intratracheal instillation (38) and less aggressive than pertracheal or transthoracic inoculation (9, 18, 33, 39, 41). However, the final inoculum concentration used for the experiments (10 log_{10} CFU/ml) was...
Cumulative mortality of rabbits inoculated with $10^{10}$ CFU of penicillin-resistant *S. pneumoniae* per ml (around 50%) was slightly higher than the 38% observed in penicillin-resistant *S. pneumoniae* in humans (37) and close to the 45 to 85% observed in untreated bacteraemic pneumococcal pneumonia (47, 48). In humans, the severity of pneumococcal pneumonia is correlated with the existence of bacteremia, which was constantly observed in our experimental model. The macroscopic and histopathological evolution observed in both penicillin-resistant and penicillin-susceptible *S. pneumoniae* pneumonia models was very similar to human pneumonia (31, 32, 40). Experimental infection begins with unilobar lesions. A rapid extension to the other lobes occurs within a few hours, accompanied by pleural effusion and bacteremia. Finally, the lesions evolve to fibrosis. Pneumococcal lung concentrations in dead rabbits ($5$ to $8$ log$_{10}$ CFU/ml) were very similar to those observed in human postmortem lung cultures (29). There was a weak correlation between bacterial concentrations and pulmonary lesions, as described in nosocomial pneumonia (28, 40, 49), even taking into account the possible lack of reproducibility by pathologists (11).

Another point of interest was that comparisons between sacrificed and pneumonia-related dead rabbits pointed out that in the first 24 h the main predictive factor of ulterior evolution was the bacterial concentration (and bacteremia); after this delay, pulmonary injuries were the most important factor. So, it is tempting to speculate that inflammatory phenomena induced by either penicillin-resistant or penicillin-susceptible *S. pneumoniae* evolve in an autonomous fashion, without strict correlation with in situ residual bacterial inoculum. Furthermore, the absence of macroscopic and histopathological differences observed between treated and untreated rabbits, while bacterial clearance was obtained, seems to reinforce this hypothesis.

**Simulation of human amoxicillin pharmacokinetics in rabbits.** Considering that the experimental pneumonia in our model closely reproduced human pathology, the humanization of antibiotic treatment appeared interesting and important. So, the second purpose of our study was to reproduce human serum pharmacokinetics of amoxicillin in rabbits. To do so, we chose an adaptation of antibiotic administration rather than a modification of the antibiotic elimination. Most of the studies simulating human pharmacokinetics by adaptation of antibiotic administration reproduced plasmatic kinetics following intravenous administration alone and/or for only a few hours (15, 16, 19, 20, 52, 53). In our study, a total of 25 simulations of human amoxicillin pharmacokinetics were performed. Results obtained after simulation were very close to the expected (human) concentrations, which were themselves far from (native) concentrations observed in rabbits after a single bolus without intravenous administration.

### TABLE 3. Pulmonary lesions and pneumococcal concentrations in rabbits with penicillin-resistant *S. pneumoniae* (strain 16089)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Result or concentration for death at the following time by the indicated cause*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>24 h</td>
</tr>
<tr>
<td></td>
<td>Pneumonia-related death</td>
</tr>
<tr>
<td>No.</td>
<td></td>
</tr>
<tr>
<td>Macroscopic score</td>
<td>22.60 ± 7.27</td>
</tr>
<tr>
<td>Histopathological score</td>
<td>12.50 ± 2.12</td>
</tr>
<tr>
<td>Pneumococcal concentration in lungs$^b$</td>
<td>6.87 ± 0.25</td>
</tr>
<tr>
<td>Pneumococcal concentration in spleen$^b$</td>
<td>5.26 ± 1.71</td>
</tr>
</tbody>
</table>

* Each value represents the mean ± SD or number and percentage. P values were determined by the Mann-Whitney test.

$^b$ Log$_{10}$ CFU/g.
subsequent infusion (23). So, by developing the Hull mathematical model (27), we were able to reproduce human pharmacokinetics fitting into an open bicompartamental model and, moreover, to mimic human serum profiles following not only intravenous but also oral administration of amoxicillin. Another theoretical advantage of this mathematical model was to calculate the extravascular antibiotic concentrations, thus allowing comparisons with measured intrapulmonary concentrations. Indeed, it was of particular interest that the measured amoxicillin pulmonary concentrations were close to the extravascular concentrations calculated from the model. Moreover, these pulmonary concentrations were near those observed in humans, even if these latter are infrequently evaluated and variable (20.8 to 43.1 mg/liter 1 h after intravenous injection of amoxicillin [1 g]) (12, 21).

Human-simulated amoxicillin treatment of experimental penicillin-resistant pneumococcal pneumonia in rabbits. The third purpose of our study was to evaluate antibiotic efficacy in our penicillin-resistant S. pneumoniae pneumonia model by simulating human pharmacokinetics of amoxicillin.

Time between inoculation and treatment initiation is an important prognostic factor, even if it cannot really be appreciated in humans. It seems overall relatively short in severe pneumonia (35). In our experimental therapeutic study, we chose a brief but sufficient delay (4 h after inoculation) to observe consolidated pulmonary pathological lesions and high pneumococcal concentrations and to start the treatment before the first untreated pneumonia-related deaths occurred (8 h after inoculation). Lung lesions and spleen pneumococcal concentrations observed 4 h after inoculation in our pneumonia model ensure that amoxicillin had a therapeutic and not a prophylactic effect. Treatment duration (between 32 and 34 h) allowed an evaluation 48 h after inoculation, without any carryover effect, at a time when bacterial concentrations are important in untreated rabbits.

Our experimental therapeutic study has shown that amoxicillin treatment (either four oral or five intravenous administrations of 1 g every 8 h) resulted in a very significant and similar pneumococcal clearance in lungs and spleen, for both penicillin-susceptible S. pneumoniae and penicillin-resistant S. pneumoniae pneumonia. These results were obtained reproducing current recommendations for S. pneumoniae pneumo-

FIG. 7. Pharmacokinetics of amoxicillin in rabbits and open bicompartamental modelization. Symbols: ---, calculated concentrations; —, measured concentrations.

Left

FIG. 8. Human amoxicillin pharmacokinetics simulation in rabbits, reproducing human serum profiles following 1-g dose administered intravenously (A) or orally (B). Symbols: —, obtained concentrations under the human pharmacokinetics simulation; ---, native concentrations without the controlled infusions; —, expected human concentrations.

Right
penicillin-susceptible strain), whereas the total area under the curve was greater in intravenous than in oral arms (320 versus 240 mg·h⁻¹·liter⁻¹).

In conclusion, we developed a penicillin-resistant *S. pneumoniae* experimental pneumonia in immunocompetent rabbits, which is easy to reproduce and very close to bacteremic pneumococcal pneumonia in humans. Human amoxicillin serum profile simulation in rabbits, corresponding to an open bicompartamental model, was realized in an easy and reproducible fashion. This experimental therapeutic study permitted the assessment of the efficacy of amoxicillin (reproducing a 3-g/day oral administration) to obtain pneumococcal clearance and survival improvement at 48 h, even with penicillin-resistant *S. pneumoniae* (MIC = 4 mg/liter). This work may permit a better understanding of pneumonia physiopathology, including inflammatory response study, and an evaluation of different therapeutic approaches to penicillin-resistant *S. pneumoniae* pneumonia.

### ACKNOWLEDGMENT

This study was supported by a grant from MEDEX Society.

### REFERENCES


23. Hekster, Y., A. Baars, T. Vree, B. van Klungelen, and A. Rutgers. 1979. Comparison of the determination of β-lactam antibiotic drugs in plasma of